Czech National Bank Buys 3,172 Shares of Hologic, Inc. (NASDAQ:HOLX)

Czech National Bank grew its stake in Hologic, Inc. (NASDAQ:HOLX) by 7.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 44,473 shares of the medical equipment provider’s stock after buying an additional 3,172 shares during the quarter. Czech National Bank’s holdings in Hologic were worth $3,302,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in HOLX. International Assets Investment Management LLC bought a new position in shares of Hologic in the fourth quarter worth about $950,000. Allworth Financial LP grew its position in shares of Hologic by 39.3% during the fourth quarter. Allworth Financial LP now owns 634 shares of the medical equipment provider’s stock valued at $45,000 after purchasing an additional 179 shares in the last quarter. Bleakley Financial Group LLC increased its holdings in shares of Hologic by 6.4% in the fourth quarter. Bleakley Financial Group LLC now owns 4,576 shares of the medical equipment provider’s stock worth $327,000 after purchasing an additional 274 shares during the last quarter. Sequoia Financial Advisors LLC lifted its position in shares of Hologic by 22.0% in the fourth quarter. Sequoia Financial Advisors LLC now owns 6,598 shares of the medical equipment provider’s stock worth $471,000 after buying an additional 1,191 shares in the last quarter. Finally, Cerity Partners LLC bought a new position in Hologic during the fourth quarter valued at approximately $390,000. 94.73% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Stephens reiterated an “overweight” rating and set a $92.00 target price on shares of Hologic in a research report on Tuesday, July 30th. StockNews.com downgraded Hologic from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Royal Bank of Canada boosted their price target on Hologic from $81.00 to $82.00 and gave the company a “sector perform” rating in a report on Tuesday, July 30th. Needham & Company LLC reissued a “buy” rating and set a $90.00 target price on shares of Hologic in a research report on Tuesday, July 30th. Finally, JPMorgan Chase & Co. lifted their price target on Hologic from $91.00 to $95.00 and gave the company an “overweight” rating in a report on Tuesday, July 30th. Four analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $87.60.

Insider Buying and Selling

In related news, insider Brandon Schnittker sold 476 shares of the firm’s stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total transaction of $39,560.36. Following the sale, the insider now owns 3,735 shares in the company, valued at $310,415.85. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, Director Christiana Stamoulis sold 9,039 shares of the business’s stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $79.50, for a total value of $718,600.50. Following the completion of the sale, the director now owns 45,472 shares of the company’s stock, valued at approximately $3,615,024. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Brandon Schnittker sold 476 shares of the stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total transaction of $39,560.36. Following the transaction, the insider now directly owns 3,735 shares in the company, valued at $310,415.85. The disclosure for this sale can be found here. Insiders have sold a total of 18,280 shares of company stock valued at $1,469,973 over the last ninety days. Company insiders own 1.75% of the company’s stock.

Hologic Stock Performance

Shares of HOLX stock traded down $1.58 during mid-day trading on Monday, reaching $82.06. The stock had a trading volume of 529,835 shares, compared to its average volume of 1,641,894. The business’s fifty day moving average is $76.29 and its 200-day moving average is $75.67. The company has a current ratio of 3.99, a quick ratio of 3.29 and a debt-to-equity ratio of 0.51. The firm has a market cap of $19.15 billion, a price-to-earnings ratio of 42.67, a PEG ratio of 2.64 and a beta of 0.99. Hologic, Inc. has a 1-year low of $64.02 and a 1-year high of $84.67.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.04. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The company had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1 billion. During the same period last year, the firm posted $0.93 EPS. Hologic’s revenue for the quarter was up 2.7% compared to the same quarter last year. On average, research analysts forecast that Hologic, Inc. will post 4.08 earnings per share for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.